Navigation Links
Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies
Date:7/1/2008

SOUTH EASTON, Mass., July 1 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that scientists from the New York University ("NYU") School of Medicine and the Brooklyn Hospital Center presented results yesterday on advances they made in the areas of breast and colon cancer, stroke, and in vitro fertilization ("IVF"). The results were generated in studies using PBI's patented pressure cycling technology ("PCT") and patent-pending PCT-dependent ProteoSolve-LRS protein extraction kit. The presentations were made at the 2nd Annual Advances in Biomolecular Engineering: Protein Design Symposium, sponsored by the New York Academy of Sciences.

Dr. Paul H. Pevsner, NYU School of Medicine (Department of Pharmacology) and principle investigator for the research studies, commented: "PCT is critical to our work. This novel, cutting-edge technology consistently gives us rapid and reliable extraction of proteins from our important samples. In addition -- and this is very exciting -- PCT has given us the additional extraordinary benefits of not only greater protein yield, but the extraction of proteins not previously identified in these types of samples. Consequently, we believe that the use of PCT, more than the use of any extraction technology available today, could lead to the discovery of new biomarkers for cancer and stroke, which in turn could lead to the development of new diagnostics and therapeutics to combat these diseases."

Dr. Pevsner continued: "Many IVF live births result in twins, triplets, and higher order births. Unfortunately, fetuses and mothers of multiple and high-order multiple pregnancies have increased morbidity and mortality. To combat this, more single embryo transfers are needed. To this end, we have been interested in identifying biomarkers for embryo viability and competence. Using PCT and ProteoSolve-LRS, we identified two proteins in IVF growth media only seen in competent embryos. These proteins may prove to be biomarkers that can enhance selection and result in more live births from single embryo transfers. These are very exciting results."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and higher) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the reported effectiveness of PCT to extract new proteins; the speed of sample preparation using PCT compared with other sample preparation methods; the importance of ProteoSolve-LRS and PCT in the reported identification of new proteins in cancer, stroke, and IVF samples; and the possibility that extraction of proteins by ProteoSolve-LRS and PCT may result in new therapeutic strategies, diagnostic paradigms, and enhanced selection for single embryo transfers. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of PCT; the possibility that due to the nature of the research being performed, other laboratories may not find the use of ProteoSolve-LRS and PCT to be as advantageous as reported by Dr. Pevsner and his colleagues; due to scientific and medical challenges, the possibility that the data generated by Dr. Pevsner and his colleagues, or that may be generated by other researchers in the future, may not be beneficial in the development of new therapeutics and diagnostics for breast and colon cancer and stroke, and may not result in more live births from single embryo transfers; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com.

Investor Contacts:

Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.

Edward H. Myles, Senior Vice President (508) 230-1828 (T)

of Finance & CFO


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
2. Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
3. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
4. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
5. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
6. New Study Linking High Normal Blood Pressure to Significant Cardiovascular Risk
7. New Pharma Business Model Increases Pressure on Staff Communicating Trial Data
8. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
9. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
10. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
11. Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Boehringer Ingelheim announced today ... Equality Index (CEI). This is the ninth time that ... designated as a Best Place to Work for LGBT ... CEI is a national benchmarking report on corporate policies ... bisexual and transgender (LGBT) employees. "We ...
(Date:12/8/2016)... December 8, 2016 According to a new market ... Sleep, Fetal), Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart ... MarketsandMarkets, the global market, in terms of value, is projected to reach ... CAGR of 18.0% during the forecast period. ... ...
(Date:12/8/2016)... FRANCISCO , Dec. 8, 2016 ... today announced that it has closed a $23 ... McKesson Ventures and OrbiMed. The company seeks to ... time physicians spend on mandated EHR documentation. The ... scribe service that frees doctors from 3 hours ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... CURE Media Group, the nation’s leading digital and print media ... Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President Michael ... Media Group is honored to team up with Upstage Lung Cancer in order to ...
(Date:12/8/2016)... ... 08, 2016 , ... SunView Software aims to redefine IT ... both engaging and easy to use. Coming off the heels of a successful ... its plans to roll out new AI-powered self-service enhancements to help organizations implement ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... San Francisco, California (PRWEB) , ... December 08, 2016 , ... ... health coaches, has raised an $18M Series B led by Canvas Ventures . ... use the capital to scale its mobile platform to serve more consumers who are ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... that serve communities in and around the greater Phoenix metropolitan region, is announcing ... Connection. , The mission of the Homeless Youth Connection is to promote community ...
Breaking Medicine News(10 mins):